Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Google Inc (GOOG) vs Heron Therapeutics Inc (HRTX) Price & Performance

Google IncTrade
Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Google Inc vs Heron Therapeutics Inc — how do they compare? Google Inc trades at $347.96 (market cap $4.24T), while Heron Therapeutics Inc trades at $0.38 (market cap $68.01M). The key difference: Google Inc is far larger — about 62343.8× Heron Therapeutics Inc's market cap, and Google Inc pays a 0.26% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Google Inc for 137 Days and Heron Therapeutics Inc for 35 Days on average.

GOOGHRTX
Market Cap
$4.24T$68.01M
Volume
13,937,9021,891,941
Sector
MediaHealth
52-Week High
$399.06$1.49
52-Week Low
$237.49$0.27
Typical Hold Time
137 Days35 Days
Enterprise Value
$4.13T$174.75M
Dividend Yield
0.26%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Google Inc

Alphabet (GOOG) trades at $347.37, up 0.81% with strong bullish technical signals. The company demonstrates exceptional fundamental strength with 2025 revenue of $402.84B and net income of $132.17B, maintaining robust profitability margins. Recent earnings beats and aggressive AI investments highlight growth momentum, though capital expenditure spikes have raised free cash flow concerns. Analyst consensus remains overwhelmingly positive with 87% buy ratings and a $435.24 price target.

Alphabet presents a compelling growth story with dominant market positioning and AI leadership, though investors face risks from regulatory scrutiny, intense competition, and significant capital expenditure requirements. The stock's current valuation appears reasonable relative to growth prospects, with technical indicators supporting near-term upside potential toward resistance levels around $350-352.

Heron Therapeutics Inc

Heron Therapeutics (HRTX) trades at $0.39, up 0.95% with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings discussions.

The outlook remains challenged by persistent losses and negative margins, though strong analyst support suggests potential upside. Key risks include execution on sales targets and achieving profitability. The stock's low price near 52-week lows presents speculative opportunity but requires careful risk management given financial performance.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

GOOG
17% Buy83% Sell
Avg holding period · 137 Days
HRTX
8% Buy92% Sell
Avg holding period · 35 Days

Top news

Latest headlines on both assets

About Google Inc

Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.

Read more on GOOG →

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX →